The Pharmacology of Two-Pore Domain Potassium Channels.
The Pharmacology of Two-Pore Domain Potassium Channels.
复制标题
DOI:
10.1007/164_2021_462
复制
发表时间:
2021-04
影响因子:
--
通讯作者:
Jordie M Kamuene;Yu Xu;L. Plant
中科院分区:
文献类型:
--
作者:
Jordie M Kamuene;Yu Xu;L. Plant
Two-pore domain potassium channels are formed by subunits that each contain two pore-loops moieties. Whether the channels are expressed in yeast or the human central nervous system, two subunits come together to form a single potassium selective pore. TOK1, the first two-domain channel was cloned fromSaccharomyces cerevisiaein 1995 and soon thereafter, 15 distinct K2Psubunits were identified in the human genome. The human K2Pchannels are stratified into six K2Psubfamilies based on sequence as well as physiological or pharmacological similarities. Functional K2Pchannels pass background (or “leak”) K+currents that shape the membrane potential and excitability of cells in a broad range of tissues. In the years since they were first described, classical functional assays, latterly coupled with state-of-the-art structural and computational studies have revealed the mechanistic basis of K2Pchannel gating in response to specific physicochemical or pharmacological stimuli. The growing appreciation that K2Pchannels can play a pivotal role in the pathophysiology of a growing spectrum of diseases makes a compelling case for K2Pchannels as targets for drug discovery. Here, we summarize recent advances in unraveling the structure, function, and pharmacology of the K2P channels.